Merck KGaA and Pfizer say drug failed to meet primary endpoints in late-stage ovarian cancer trial

Merck KGaA and Pfizer Inc. said early Monday that the cancer immunotherapy avelumab did not meet the primary endpoints of a phase 3 ovarian cancer trial.